glp-1 receptor agonists for weight loss Management Study finds GLP-1 receptor agonists

T.ShenL.ZuoL.ShashikanthN.OngM.WuL.et al (2019)

This article examines the potential anti-inflammatory mechanisms of GLP-1 medications, compares available agents, and discusses what patients should consider when speaking with their GP about these treatments

it can cause some health concerns

Several large-scale cardiovascular outcome trials (including LEADER, SUSTAIN-6, and REWIND) have shown that certain GLP-1 receptor agonists liraglutide, semaglutide, and dulaglutide reduce the risk of major adverse cardiovascular events such as heart attack, stroke, and cardiovascular death in people with established cardiovascular disease or multiple cardiovascular risk factors